Verrica Pharmaceuticals Inc. (VRCA) Tops Q2 EPS by 4c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/23/2026
- Nasdaq futures drop over 2% on concerns over AI buildout costs, Fed rate outlook
- Nasdaq 100 set to shed over $1 trillion as tech selloff deepens; SpaceX slides
- Oil prices fall as investors focus on Hormuz flows after peace talks
- SpaceX slides, tech stocks dip — what’s moving markets
- Deutsche Bank cuts gold outlook as Fed repricing weighs on prices
- Spain's ex-transport minister sentenced to 24 years for corruption
- Exclusive-China robot-hand-building unicorn Linkerbot targets $6 billion valuation
- China, US, UAE police arrest 276 telecom fraud suspects in Dubai
- Li Auto Inc. (LI) Breaks Ground on Chips R&D and Production Base
- 'Equal and opposite': BTIG's Krinsky sees sharp reversal ahead for chip stocks
Verrica Pharmaceuticals Reports Second Quarter 2024 Financial Results
August 14, 2024 7:45 AM EDT- Reports YCANTH® revenue, net of $4.9M for second quarter of 2024 along with the expansion of YCANTHs distribution footprint to include Cencora, Inc. as a specialty distributor
-Â Announces positive preliminary topline results of Phase 2 clinical study of VP-315 for the treatment of patients with basal cell carcinoma
-Â Continues to progress preparation for global Phase 3 Common Warts trial with initiation expected in 1H 2025
-Â Conference Call Scheduled for Today at 8:30 am ETÂ
WEST CHESTER, Pa., Aug. 14, 2024 (GLOBE NEWSWIRE) -- Verrica Pharmaceuticals Inc.... More
